Y-mAbs Therapeutics, Inc. (YMAB)

17,25 +0,76 (+4,61%) Börsenschluss: 04:00PM EDT

Y-mAbs Therapeutics, Inc.

230 Park Avenue
Suite 3350
New York, NY 10169
United States
646 885 8505
https://www.ymabs.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 100

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Susan Smith	Senior VP & Chief Commercial Officer	710k	N/A	1971
Mr. Michael Rossi	CEO, President & Director	N/A	N/A	1971
Mr. Joris Wiel Jan Wilms	Senior VP & COO	N/A	N/A	1974
Dr. Torben Lund-Hansen M.Sc., Ph.D.	Senior VP & CTO	N/A	N/A	1951
Ms. Courtney Dugan	Vice President of Investor Relations	N/A	N/A	N/A
Dr. Vignesh Rajah M.B.A., MBBS	Senior VP & Chief Medical Officer	406,27k	N/A	1965

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Corporate Governance

Y-mAbs Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 5, Vorstand: 7, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.